Price (delayed)
$1.06
Market cap
$65.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.32
Enterprise value
$64.54M
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype
There are no recent dividends present for PYXS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.